
Sign up to save your podcasts
Or


Known for his early drug development research for breast cancer, Dr. Giuseppe Curigliano joins Dr. Matt Birnholz at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain to talk about the latest research in treatment developments for triple-negative breast cancer as well as insights on what’s coming ahead on the future horizons for this cancer subtype.
 By ReachMD
By ReachMDKnown for his early drug development research for breast cancer, Dr. Giuseppe Curigliano joins Dr. Matt Birnholz at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain to talk about the latest research in treatment developments for triple-negative breast cancer as well as insights on what’s coming ahead on the future horizons for this cancer subtype.

1 Listeners

3 Listeners

3 Listeners

0 Listeners

6 Listeners

15 Listeners

18 Listeners